JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

Details
By J. Smith
J. Smith
Privacy
Last Updated: 27 April 2025
Hits: 680
  • Privacy Policy
  • Data Protection
  • User Data
  • Cookie Policy
  • Data Security

Privacy

This privacy policy ("policy") will help you understand how JCS/T2D ("us", "we", "our") uses and protects the data you provide to us when you visit and use [blog URL] ("blog", "service").

We reserve the right to change this policy at any given time, of which you will be promptly updated. If you want to make sure that you are up to date with the latest changes, we advise you to frequently visit this page.

What User Data We Collect

When you visit the site, we may collect the following data:

  • Your IP address.
  • Your contact information and email address (if you provide them).
  • Data profile regarding your online behavior on our site.

Why We Collect Your Data

We are collecting your data for several reasons:

  • To better understand your needs.
  • To improve our services and products.
  • To customize our site according to your online behavior and personal preferences.

Safeguarding and Securing the Data

JCS/T2D is committed to securing your data and keeping it confidential. JCS/T2D has done all in its power to prevent data theft, unauthorized access, and disclosure by implementing the latest technologies and software, which help us safeguard all the information we collect online.

Our Cookie Policy

Once you agree to allow our site to use cookies, you also agree to use the data it collects regarding your online behavior (analyze web traffic, web pages you visit and spend the most time on).

The data we collect by using cookies is used to customize our blog to your needs. After we use the data for statistical analysis, the data is completely removed from our systems.

Please note that cookies don't allow us to gain control of your computer in any way. They are strictly used to monitor which pages you find useful and which you do not so that we can provide a better experience for you.

If you want to disable cookies, you can do it by accessing the settings of your internet browser. You can visit https://www.internetcookies.com, which contains comprehensive information on how to do this on a wide variety of browsers and devices.

Links to Other Websites

Our blog contains links that lead to other websites. If you click on these links JCS/T2D is not held responsible for your data and privacy protection. Visiting those websites is not governed by this privacy policy agreement. Make sure to read the privacy policy documentation of the website you go to from our website.

Distribution of your Personal Data

JCS/T2D will not lease, sell or distribute your personal information to any third parties, unless we have your permission. We might do so if the law forces us.

Articles

  • Join the 5K@EASD Virtual Run/Walk for Diabetes Awareness 2024
  • Continuous Glucose Monitoring: A Game Changer for Type 2 Diabetes Management
  • Types of Diabetes
  • Diabetes and Eye Health
  • How GLP-1 Receptor Agonists Can Help You Manage Type 2 Diabetes
  • Understanding the Link Between GLP-1 Receptor Agonists and Reduced Colorectal Cancer Risk in Type 2 Diabetes Patients
  • Navigating Prior Authorization for Type 2 Diabetes Treatments
  • Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
  • GLP-1 RAs and Gastroparesis (Stomach Paralysis)
  • How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
  • Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • A New Era in Diabetes Management: Once-Weekly Insulin Icodec
  • Mounjaro Shortage: A Challenge for Diabetes and Obesity Patients
  • From Lab to Pharmacy: Navigating the Clinical Drug Trials and Approval Process in the US and EU
  • Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment
  • Data Analytics for Type 2 Diabetes
  • Understanding the Link Between Type 2 Diabetes and Chronic Kidney Disease
  • New Research Reveals the Hidden Complexity of Insulin Resistance
  • Join the 5K@ADA Virtual Run/Walk for Diabetes Awareness 2024
  • Mounjaro: A New Player in the GLP-1 Arena for Type 2 Diabetes Management

News

October 2025

  • FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
  • Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
  • Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
  • Semaglutide’s Heart Benefits Extend Beyond Weight Loss
  • Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

  • CVS Caremark Faces Lawsuit Over Dropping Zepbound
  • Dexcom Introduces Smart Basal at EASD 2025
  • Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
  • Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
  • Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
  • Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
  • Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

  • FDA Approves Wegovy for MASH Treatment
  • FDA Expands Repatha Access to More High-Risk Adults
  • Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
  • Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
  • Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
  • Signos Press Release Raises Questions About FDA Clearance Claims
  • Teva Launches First Generic GLP-1 for Obesity
  • Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Semaglutide
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • Diabetes
  • Obesity
  • FDA Approval
  • Diabetes Management
  • Cardiovascular Health
  • Mounjaro
  • SELECT Trial
  • Continuous Glucose Monitoring
  • GLP-1 Therapy
  • Obesity Management
  • Metabolic Health
  • Orforglipron
  • Disease Modification
  • Dexcom
  • CGM
  • Rybelsus
  • Clinical Trials
  • Oral Semaglutide
  • FDA
  • Diabetes Treatment

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
  • Privacy
  • Privacy
 
Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.